Scotiabank raised the firm’s price target on Travere Therapeutics (TVTX) to $31 from $30 and keeps an Outperform rating on the shares. The company reported “impressive” results for Fislapri in IgA nephropathy, IgAN, in Q2, and the firm believes there are numerous reasons why this outperformance can continue, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $32 from $30 at Wedbush
- Travere Therapeutics Reports Strong Q2 2025 Growth
- Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics
- Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
- Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion